Twist Bioscience (NASDAQ:TWST) Stock Price Target Lowered at TD Cowen

Twist Bioscience (NASDAQ:TWST) had its price target reduced by TD Cowen from $190.00 to $137.00 in a research report sent to investors on Friday morning, Marketbeat.com reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group began coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They issued a “hold” rating and a $150.00 price target on the stock. BWS Financial reissued a “sell” rating and issued a $45.00 target price on shares of Twist Bioscience in a research report on Friday, September 18th. Guggenheim upped their price target on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Piper Sandler raised their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Finally, Barclays boosted their price objective on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $141.00.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $111.60 on Friday. The firm has a market cap of $7.00 billion, a PE ratio of -53.40 and a beta of 2.25. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 52 week low of $23.30 and a 52 week high of $219.71. The business’s fifty day simple moving average is $150.23 and its 200-day simple moving average is $93.07.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative net margin of 28.34% and a negative return on equity of 27.53%. The firm had revenue of $126.64 million for the quarter, compared to analyst estimates of $123.55 million. The firm’s revenue for the quarter was up 26.7% on a year-over-year basis. Equities analysts forecast that Twist Bioscience will post -1.52 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 356,546 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the completion of the sale, the chief executive officer owned 620,589 shares in the company, valued at approximately $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 8,057 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the transaction, the chief financial officer owned 100,576 shares in the company, valued at approximately $18,996,794.88. This trade represents a 7.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is currently owned by corporate insiders.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. E. Ohman J or Asset Management AB acquired a new position in Twist Bioscience during the 2nd quarter worth approximately $853,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Twist Bioscience in the first quarter valued at approximately $22,563,000. Bank of America Corp DE grew its holdings in Twist Bioscience by 46.3% during the first quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock worth $27,764,000 after acquiring an additional 184,907 shares during the period. William Blair Investment Management LLC acquired a new stake in Twist Bioscience in the second quarter valued at $223,722,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Twist Bioscience in the second quarter valued at $8,215,000.

Key Stories Impacting Twist Bioscience

Here are a few of the latest stories about TWST:

• Positive Sentiment: Fiscal Q4 revenue rose about 27% year over year to $126.6 million, beating consensus, while the $0.32-per-share loss was narrower than analysts expected. AI drug-discovery revenue totaled $59.1 million for fiscal 2026. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million is only modestly above the $549 million consensus, which may have disappointed investors looking for a stronger outlook. Article: Twist Bio slips despite Q4 beat after underwhelming FY27 outlook
• Negative Sentiment: Leerink Partners cut its price target to $175 from $190, TD Cowen to $137 from $190, and Baird to $135 from $187. Each maintained a positive rating—outperform or buy—but the reductions indicate more cautious valuation expectations. Leerink Partners ratings

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.